AstraZeneca CEO discusses leaving London for US and Japan facing new, bigger tariff - Stock markets updates and business news ...

President Trump’s threat of a 35% tariff on imports from Japan weighed on the Nikkei 225, which stands about 0.4% lower. The ...

Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...

Gilt yields spike on Reeves exit speculation and AstraZeneca CEO discusses leaving London - Stock markets updates and ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

Top riser on the FTSE 350 today is B&M European Value Retail SA (LSE:BME) after analysts at RBC Capital Markets joined those ...

The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate ...

Cambridge-based AstraZeneca looks like it has set another drug on its way to blockbuster status - Datroway for the treatment ...

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in the West. The Japanese Ministry of ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said Datroway has secured US Food & Drug Administration approval for use in adult patients with previously treated advanced ...